HomeInsightsPE

Natco Pharma Ltd PE Ratio

Natco Pharma Ltd PE Ratio

stocks purchased

₹ 8.6 Cr

Volume transacted

stocks purchased

60.1 K

stocks traded

Last Updated time: 10 Oct 9.00 AM

Image

Natco Pharma Ltd

NSE: NATCOPHARM

PE

15.7

Last updated: 10 Oct 9.00 AM

Key Highlights

  • The P/E Ratio of Natco Pharma Ltd is 15.7 as of 10 Oct 9.00 AM.
  • The P/E Ratio of Natco Pharma Ltd changed from 16.2 on March 2019 to 12.3 on March 2024 . This represents a CAGR of -4.49% over 6 years. .
  • The Latest Trading Price of Natco Pharma Ltd is ₹ 1434 as of 10 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Natco Pharma Ltd

No data available

Company Fundamentals for Natco Pharma Ltd

No data available

Image

Natco Pharma Ltd

NSE: NATCOPHARM

PRICE

1434.9

-40.35 (-2.74%)

stock direction

Last updated: 10 Oct 15:30

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Natco Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
10 Oct 20241434.9
09 Oct 20241475.25
08 Oct 20241426
07 Oct 20241401.6
04 Oct 20241354.65
03 Oct 20241362.6
01 Oct 20241400.4
30 Sep 20241420.35
27 Sep 20241413.2
26 Sep 20241382.85

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Natco Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Natco Pharma Ltd1525,700
Sun Pharmaceuticals Industries Ltd424,52,850
Divis Laboratories Ltd941,57,702
Cipla Ltd291,30,709
Torrent Pharmaceuticals Ltd691,16,560
Dr Reddys Laboratories Ltd191,09,846

Key Valuation Metric of Natco Pharma Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Natco Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Natco Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Natco Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Natco Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payout of Natco Pharma Ltd

No data available

* All values are in %

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Natco Pharma Ltd News Hub

News

Natco Pharma Ltd rises for third straight session

Natco Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1460...

Read more

09 Oct 202413:05

News

Natco Pharma soars after Mylan settles Ozempic patent dispute

Natco Pharma announced that its partner, Mylan Pharmaceuticals Inc., reached a settlement ...

Read more

07 Oct 202415:28

News

Natco Pharma Ltd slips for fifth straight session

Natco Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 15...

Read more

19 Sep 202413:35

News

Natco Pharma invests USD 8 mn in bio-tech firm eGenesis

Natco Pharma announced that its wholly owned Canadian subsidiary, Natco Pharma (Canada) In...

Read more

04 Sep 202412:07

News

Natco Pharma Canada arm invests $8 mln in eGenesis

eGenesis is engaged in using its multiplex gene editing and genome engineering platform to...

Read more

04 Sep 202412:01

News

Natco Pharma Ltd spurts 1.25%, up for third straight session

Natco Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1570....

Read more

23 Aug 202413:05

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Natco Pharma Ltd

What is the current PE Ratio of Natco Pharma Ltd?

The Current PE Ratio of Natco Pharma Ltd is 15.7 as on 10 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 10 Oct 2024.

What was the PE Ratio of Natco Pharma Ltd last year?

The PE Ratio of Natco Pharma Ltd was 14.38 last year, now the PE ratio is 15.7, showing a year-on-year growth of 9.2%.

What does the PE Ratio of Natco Pharma Ltd indicate about its stock?

The PE Ratio of Natco Pharma Ltd is 15.7. This ratio indicates that investors are willing to pay 15.7 times the earnings per share for each share of Natco Pharma Ltd.

What is the PE Ratio Growth of Natco Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Natco Pharma Ltd grew by 9.2% whereas, the EPS ratio grew by 73.1.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*